A new prostate cancer test that looks for high levels of the biomarker PCA3 mRNA in urine has been launched in the European Union.
Research has suggested that, in more than 95 percent of prostate cancer cases, PCA3 is 60- to 100-fold over-expressed in prostate cancer cells, compared to normal cells.
Preliminary data indicate the PCA3 test may be more specific to prostate cancer than the traditional serum prostate specific antigen (PSA) test, which means the PCA3 test would be less likely to give false positive results.
"Only 25 to 30 percent of men who have a biopsy due to elevated PSA levels actually have prostate cancer; therefore, the majority of elevated PSA tests are the result of non-cancerous conditions," Dr Mark Emberton, senior lecturer in oncological urology at University College Hospital in London, said in a prepared statement.
"Unnecessary biopsies contribute to patient anxiety and are a burden on the healthcare system. We are optimistic that the Gen-Probe PCA3 test, used in combination with serum PSA, will further identify appropriate biopsy patients and that this will result in better detection and diagnosis of prostate cancer," Emberton added. – (HealthDayNews)